Jinal Pandya, Unjha (IN); Sandip P. Mehta, Ahmedabad (IN); Manish Umrethia, Ahmedabad (IN); Jayanta Kumar Mandal, Ahmedabad (IN); and Hiren Pansuriya, Ahmedabad (IN)
Assigned to LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed by LIQMEDS WORLDWIDE LIMITED, Middlesex (GB)
Filed on May 16, 2024, as Appl. No. 18/665,714.
Application 18/665,714 is a continuation of application No. 18/624,230, filed on Apr. 2, 2024.
Application 18/624,230 is a continuation of application No. 18/308,723, filed on Apr. 28, 2023, granted, now 11,975,006, issued on May 7, 2024.
Application 18/308,723 is a continuation of application No. 17/832,921, filed on Jun. 6, 2022, granted, now 11,666,576, issued on Jun. 6, 2023.
Application 17/832,921 is a continuation of application No. 17/403,282, filed on Aug. 16, 2021, granted, now 11,382,917, issued on Jul. 12, 2022.
Application 17/403,282 is a continuation of application No. 16/957,894, granted, now 11,464,778, issued on Oct. 11, 2022, previously published as PCT/IB2018/001462, filed on Dec. 24, 2018.
Claims priority of application No. 201721046640 (IN), filed on Dec. 26, 2017; and application No. 201821012438 (IN), filed on Apr. 2, 2018.
Prior Publication US 2024/0299396 A1, Sep. 12, 2024
1. A liquid oral pharmaceutical composition comprising
about 4 mg/mL tadalafil;
a pharmaceutically acceptable excipient comprising a wetting agent comprising ethanol, glycerin, propylene glycol, or a combination thereof in an amount of from about 200 mg/mL to about 1000 mg/mL; and
a vehicle comprising water;
wherein the pharmaceutical composition has a pH of from about 4 to about 8.